| Dr Kevin E Vorenkamp, MD | |
|
3404 Wake Forest Rd Ste 300, Raleigh, NC 27609 | |
| (919) 954-3584 | |
| (919) 954-3156 |
| Full Name | Dr Kevin E Vorenkamp |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 22 Years |
| Location | 3404 Wake Forest Rd Ste 300, Raleigh, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053364141 | NPI | - | NPPES |
| MD00138 | Other | WA | AK DSHS |
| 1053364141 | Medicaid | WA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Duke Health Raleigh Hospital | Raleigh, NC | Hospital |
| Duke Regional Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).
EXFO Inc. announced today that it has sold its Life Sciences and Industrial Division to The Riverside Company, a global private equity firm, for US$24.3 million in cash. The purchase price is subject to adjustments for minimum working capital requirements.
The study involved researchers growing fruits and vegetables on a 725 acre area where fields were split into two so that conventional and organic produce could be grown side by side.
Researchers from the INCLIVA Health Research Institute, the Clinical Hospital of Valencia, and the University of Valencia (UV) have participated in a study, the results of which have just been published in Science, which paves the way for a better understanding of muscle injury.
› Verified 2 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).
EXFO Inc. announced today that it has sold its Life Sciences and Industrial Division to The Riverside Company, a global private equity firm, for US$24.3 million in cash. The purchase price is subject to adjustments for minimum working capital requirements.
The study involved researchers growing fruits and vegetables on a 725 acre area where fields were split into two so that conventional and organic produce could be grown side by side.
Researchers from the INCLIVA Health Research Institute, the Clinical Hospital of Valencia, and the University of Valencia (UV) have participated in a study, the results of which have just been published in Science, which paves the way for a better understanding of muscle injury.
› Verified 2 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).
EXFO Inc. announced today that it has sold its Life Sciences and Industrial Division to The Riverside Company, a global private equity firm, for US$24.3 million in cash. The purchase price is subject to adjustments for minimum working capital requirements.
The study involved researchers growing fruits and vegetables on a 725 acre area where fields were split into two so that conventional and organic produce could be grown side by side.
Researchers from the INCLIVA Health Research Institute, the Clinical Hospital of Valencia, and the University of Valencia (UV) have participated in a study, the results of which have just been published in Science, which paves the way for a better understanding of muscle injury.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin E Vorenkamp, MD 1100 9th Ave, Ms:m4-pfs, Seattle, WA 98101-2756 Ph: (206) 515-5811 | Dr Kevin E Vorenkamp, MD 3404 Wake Forest Rd Ste 300, Raleigh, NC 27609 Ph: (919) 954-3584 |
News Archive
Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).
EXFO Inc. announced today that it has sold its Life Sciences and Industrial Division to The Riverside Company, a global private equity firm, for US$24.3 million in cash. The purchase price is subject to adjustments for minimum working capital requirements.
The study involved researchers growing fruits and vegetables on a 725 acre area where fields were split into two so that conventional and organic produce could be grown side by side.
Researchers from the INCLIVA Health Research Institute, the Clinical Hospital of Valencia, and the University of Valencia (UV) have participated in a study, the results of which have just been published in Science, which paves the way for a better understanding of muscle injury.
› Verified 2 days ago
Dr. Robert A Royster Iii, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4420 Lake Boone Trl, Raleigh, NC 27607 Phone: 919-784-3241 Fax: 919-784-6862 | |
James Belknap Collawn, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3000 New Bern Ave, Raleigh, NC 27610 Phone: 919-350-5645 | |
Sean Christopher Selig, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4420 Lake Boone Trl, Raleigh, NC 27607 Phone: 919-784-3100 | |
Dr. Peter Albert Modrow, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 312 Meeting House Cir, Raleigh, NC 27615 Phone: 919-870-8833 Fax: 919-870-8833 | |
Jeremy Kenneth Reading, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3000 New Bern Ave, Raleigh, NC 27610 Phone: 919-350-5645 Fax: 919-350-7385 | |
Michael Winn Hauser, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4420 Lake Boone Trl, Raleigh, NC 27607 Phone: 919-784-3034 |